Basiliximab

Basiliximab is a chimeric murine monoclonal anti-interleukin-2 receptor (CD25) antibody.Basiliximab is used in conjuntion with other immunosuppressant drugs in patients undergoing organ transplantation to prevent graft rejection.


Brands
Adult Dose
Dose: 20 mg
Single Dose: 20 (20)
Frequency: As recommended.
Route: IV Inf
Instructions: 665 ug/min For 30 minutes, repeat after 4 days, as required.
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose: 12 mg/sq.meter
Single Dose: 22 (22)
Frequency: As recommended.
Route: IV Infusion
Instructions: Over20-30 minutes, repeate after 4 days
Characteristics
. It is of Semi Synthetic origin and belongs to Protein. It belongs to CDC Biologicals and Monoclonal Antibody pharmacological group.
Contraindications
Basiliximab is contraindicated in conditions like Hypersensitivity,Pregnancy,Breast feeding.
Effects
The severe or irreversible adverse effects of Basiliximab, which give rise to further complications include Hypertension, Urinary tract infection.The symptomatic adverse reactions produced by Basiliximab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Fever, Dyspnea, Constipation, Insomnia, Abdominal pain, Peripheral edema, Pain, Dysuria, Dyspepsia, Weight gain, Tremor, Cough, Rhinitis.
Indications
Basiliximab is primarily indicated in conditions like Organ transplantation, Prophylaxis of acute graft rejection episodes, Prophylaxis of acute rejection in allogenic renal transplantation.
Interactions
No data regarding the interactions of Basiliximab was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj Store in refrigerator.
Warnings
Basiliximab is not recommended for use during pregnancy or lactation. Immunosuppressant drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurement of hemoglobin concentration should be carried out routinely, help to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes and should not be inhaled.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.